In addition, a significantly higher proportion of EGFR compound mutations were detected (43.35% vs 10.12%, P < 0.0001, for all EGFR mutations) (Figures 4C, D), and the proportion of EGFR G719X + L861Q (21.10% vs 3.38%, P < 0.0001) and EGFR G719X + S768I (19.65% vs 2.82%, P < 0.0001) subtypes was significantly higher in patients with NSCLC from Qujing (Figures 4E, F). Here, EGFR is linked to non-small cell lung carcinoma.